Previous studies showed that both D281G and R248W mutants transactivate expression of tumor progression-related genes such as MYC, PCNA, EGFR, and EGR1; the D281G mutant shows an even greater transactivating activity than R248W in these studies [41,42,43,44]. This evidence concerns the gene EGFR and neoplasm.